OCULAR CHANGES IN PATIENTS ON LONG TREATMENT WITH HYDROXYCHLOROQUINE AN ORIGINAL RESEARCH WITH REVIEW OF LITERATURE

Main Article Content

Anuradha Singh Sagarika Patyal Vivek Vasudev Vijay Sharma Hemant Singh Trehan

Abstract

Introduction: To study the ocular changes in patients on long term treatment with Hydroxychloroquine (HCQ); and detect means for early detection of toxicity.
Methods: We conducted a cross-sectional observational study at a tertiary care hospital, in which 100 patients, male and female, aged 35 years or more, taking HCQ for 5 years or more were included. Patients with any known ocular or systemic diseases were not included. Indication, dosage, duration and cumulative dose of HCQ intake were recorded. History of ocular symptoms, visual acuity, colour vision, complete ophthalmic examination, visual field using Amsler grid and 10-2 Humphrey’s automated fields (HVF), Spectral Domain Optical Coherence Tomography (SD-OCT), colour fundus photography, fundus fluorescein angiography (FFA) and fundus autofluorescence (FAF) were recorded. The data was analyzed using descriptive and inferential analysis.
Result: 15% of the study population showed signs of HCQ related ocular toxicity. 17%, 21% and 10% patients had abnormal SD-OCT, HVF and FAF findings respectively.
Conclusion: HCQ related ocular toxicity has been found in patients in the absence of symptoms. Objective tests like HVF, SD- OCT and FAF were more useful in early detection of toxicity than subjective tests such as Amsler grid, colour vision and FFA.

Keywords

Hydroxychloroquine, Bull’s eye maculopathy, Spectral Domain Optical Coherence Tomography, Fundus autofluorescence

Article Details

How to Cite
SINGH, Anuradha et al. OCULAR CHANGES IN PATIENTS ON LONG TREATMENT WITH HYDROXYCHLOROQUINE. International Journal of Retina, [S.l.], v. 4, n. 2, p. 111, sep. 2021. ISSN 2614-8536. Available at: <https://www.ijretina.com/index.php/ijretina/article/view/170>. Date accessed: 23 oct. 2021. doi: https://doi.org/10.35479/ijretina.2021.vol004.iss002.170.
Section
Research Articles

References

1. Santaella RM, Fraunfelder FW, Ocular adverse effects associated with systemic medications, Drugs, 67(1), 2007, 75-93.

2. N.J. Olsen, M.A. Schleich and D.R. Karp, Multifaceted effects of hydroxychloroquine in human diseas, Semin Arthritis Rheum. , 43(2), 2013, 264 - 72.

3. Leslie Raphael de Moura Ferraz et al. Clinical, pharmacokinetic and technological aspects of the hydroxychloroquine sulphate. IOSR J Pharmacol. 4(11), 2014; 53-64.

4. Geamånu A et al. Retinal toxicity associated with chronic exposure to hydroxychloroquine and its ocular screening.Review. J Med Life. 7(3), 2014; 322-326.

5. Sundelin S, Terman A. Different effects of chloroquine and hydroxychloroquine on lysosomal function in cultured retinal pigment epithelial cells. APMIS. 110(6), 2002; 481-489.

6. Mavrikakis I, Sfikakis PP, Mavrikakis E, et al. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. Ophthalmology. 2003; 110(7):1321-1326.

7. Chen E, Brown DM, Benz MS, et al. Spectral-domain optical coherence tomography as an effective screening test for hydroxychloroquine retinopathy (the “flying saucer” sign). Clinical Ophthalmology. 2010; 4:1151-1158.

8. Paulose RM, Chhablani J, Jhingan M. Update on hydroxychloroquine retinopathy. Kerala J Ophthalmol. 29(1), 2017; 9-13.

9. Tangtavorn N et al. Incidence of and risk factors for chloroquine and hydroxychloroquine retinopathy in Thai rheumatologist patients. Clin Ophthalmol. 10, 2016; 2179-2185.

10. Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res. 2010; 62:775-784.

11. Eo D, Lee M G, Ham Don-II et al. Frequency and clinical characteristics of hydroxychloroquine retinopathy in Korean patients with rheamatologic diseases. J Korean Med Sci. 2017 March; 32(3): 522-527.

12. Malviya A N, Kapoor S K, Singh R R et al. Prevalence of rheumatoid arthritis in the adult
Indian population. Rheumatol Int. 1993; 13:131.

13. Mavrikakis M, Papazoglou S, Sfikakis PP, et al. Retinal toxicity in long term hydroxychloroquine treatment. Ann Rheum Dis. 1996; 55:187-189.

14. Rynes RI. Ophthalmologic safety for long-term hydroxychloroquine sulphate treatment. Am J Med. 1983; 75(1):35-39.

15. Mavrikakis I, Sfikakis PP, Mavrikakis E, et al. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. Ophthalmology. 2003; 110(7):1321-1326.

16. Chen E, Brown DM, Benz MS, et al. Spectral-domain optical coherence tomography as an effective screening test for hydroxychloroquine retinopathy (the “flying saucer” sign). Clinical Ophthalmology. 2010; 4:1151-1158.

17. Marmor MF, Kellner U, Lai TYY, et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology. 2016; 123(6):1386-1394.